FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated avera	ge burden									

0.5

hours per response:

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Vasista Vittal						2. Issuer Name and Ticker or Trading Symbol REGENXBIO Inc. [RGNX]								Check all	applicable) Director	10%	g Person(s) to Issuer 10% Owner Other (specify	
(Last) (First) (Middle) C/O REGENXBIO INC. 9600 BLACKWELL ROAD, SUITE 210						3. Date of Earliest Transaction (Month/Day/Year) 07/17/2017									elow)			
(Street) ROCKV	ILLE N	4D	20850 (Zip)		4. If Amendment, Date of Original Filed (Month/Day/Year)									Line) X F				
		Tab	le I - N	on-Deriv	/ative	Sec	uritie	s Ac	quire	d, Di	sposed o	f, or B	enefic	ally Ov	vned			
1. Title of Security (Instr. 3) 2. Transact Date (Month/Day				Execution Date,		3. Transaction Code (Instr. 8) 4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4					1 5) Se Be	Amount of ecurities eneficially wned Following eported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership				
									Code	v	Amount	(A) or (D)	Price	Tr	ansaction(s) astr. 3 and 4)		(Instr. 4)	
Common Stock ⁽¹⁾ 06/30/20					2017	17		A		911	A	\$15.7	25 ⁽²⁾	108,423	D			
Common	Common Stock 07/17/20					17			S ⁽³⁾		3,100	D	\$19.8	B1 ⁽⁴⁾	105,323	D		
		Ta	able II								osed of, convertib				ed			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		if any	med on Date, Day/Year) Day/Year) 4. Transaction Code (Instr. 8) 5. Num of Deriva Secur Acqui (A) or Dispo of (D) (Instr. and 5)		rative rities ired r osed)	6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price Derivati Security (Instr. 5	ve derivative Securities	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)			

Explanation of Responses:

- 1. The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the REGENXBIO Inc. Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of January 1, 2017 through June 30, 2017. This transaction is exempt under Rule 16b-3(c).
- 2. In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on January 1, 2017.
- 3. This transaction was effected pursuant to a Rule 10b5-1 trading plan.
- 4. This transaction was executed in multiple trades at prices ranging from \$19.70 to \$20.05. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

/s/ Vittal Vasista

07/19/2017

lv.

** Signature of Reporting Person Date

 $Reminder: \ Report \ on \ a \ separate \ line \ for \ each \ class \ of \ securities \ beneficially \ owned \ directly \ or \ indirectly.$

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.